Amgen urges US appeals court to rule Carefirst's US antitrust claims over Enbrel
MLex Summary: Amgen filed a reply brief urging a US appeals court to reverse an order that denied the dismissal of antitrust claims over Enbrel. “CareFirst’s alleged injury exists only because the...To view the full article, register now.
Already a subscriber? Click here to view full article